NovoCure's TTFields Therapy Shows Promising Results in Phase 3 Trial
A 'potentially practice changing' therapy
In a press release Wednesday, Novocure announced that its phase 3 METIS clinical trial met its primary endpoint by demonstrating a statistically significant improvement in time to intracranial progression for patients.
Major benefit and potential practice change
Patients receiving TTFields therapy showed a median time to intracranial progression of 21.9 months compared to 11.3 months for those on supportive care alone.
What's next for Novocure investors?
Preliminary analysis of secondary endpoints like overall survival showed no statistical significance, but positive trends were noted in quality of life and progression.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.